Biomarkers of neurodegeneration and neuronal injury have the potential to improve
diagnostic accuracy, disease monitoring, prognosis, and measure treatment efficacy …

Multiple sclerosis is a highly heterogeneous disease, and the detection of neuroaxonal
damage as well as its quantification is a critical step for patients. Blood-based serum …

Neurofilament light chain (NfL) is a long-awaited blood biomarker that can provide clinically
useful information about prognosis and therapeutic efficacy in multiple sclerosis (MS). There …

Neuronal injury is a universal event that occurs in disease processes that affect both the
central and peripheral nervous systems. A blood biomarker linked to neuronal injury would …

Measurement of serum neurofilament light chain concentration (sNfL) promises to become a
convenient, cost effective and meaningful adjunct for multiple sclerosis (MS) prognostication …

A simple blood-derived biomarker is desirable in the routine management of multiple
sclerosis (MS) patients and serum neurofilament light chain (sNfL) is the most promising …

Objective To investigate the association of combined serum neurofilament light chain (sNfL)
and retinal optical coherence tomography (OCT) measurements with future disease activity …

Disability in multiple sclerosis is generally classified by sensory and motor symptoms, yet
cognitive impairment has been identified as a frequent manifestation already in the early …

Multiple sclerosis (MS) is a chronic demyelinating and neuroinflammatory disease of the
human central nervous system with complex pathoetiology, heterogeneous presentations …

Background: Serum neurofilament light (sNfL) reflects neuroaxonal damage and is now
used as an outcome in treatment trials of relapsing-remitting multiple sclerosis (RRMS) …